• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.

作者信息

Tan David, Fujiwara Noriko, Fujiwara Keiichi, Beale Philip, Kim Jae-Weon, Ng Joseph, Kim Se Ik, Evans Alison, Kim Byoung-Gie

机构信息

Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore.

Cancer Science Institute, National University of Singapore, Singapore.

出版信息

Int J Gynecol Cancer. 2023 Apr 3;33(4):628-630. doi: 10.1136/ijgc-2022-004236.

DOI:10.1136/ijgc-2022-004236
PMID:36914169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10086504/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/e782d96c879d/ijgc-2022-004236f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/f76edcb34d18/ijgc-2022-004236f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/79f64ef4c231/ijgc-2022-004236f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/e782d96c879d/ijgc-2022-004236f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/f76edcb34d18/ijgc-2022-004236f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/79f64ef4c231/ijgc-2022-004236f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a097/10086504/e782d96c879d/ijgc-2022-004236f03.jpg

相似文献

1
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.亚太妇科肿瘤试验组（APGOT）：构建一个泛亚和大洋洲的女性癌症研究组织。
Int J Gynecol Cancer. 2023 Apr 3;33(4):628-630. doi: 10.1136/ijgc-2022-004236.
2
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.亚太妇科肿瘤试验组（APGOT）：构建一个泛亚和大洋洲女性癌症研究组织。
J Gynecol Oncol. 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33.
3
Advancing women's cancer care: highlights from the Annual Meeting on Women's Cancer 2007. Report on the 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, Calif., March 3-7, 2007.推进女性癌症护理：2007年女性癌症年会亮点。妇科肿瘤学家协会第38届年会报告，加利福尼亚州圣地亚哥，2007年3月3日至7日。
Gynakol Geburtshilfliche Rundsch. 2007;47(4):240-2. doi: 10.1159/000107266.
4
The IGCS global curriculum mentorship and training program: building human capacity for gynecologic cancer treatment and research where the need is greatest.国际妇癌协会全球课程指导与培训项目：在需求最为迫切之处培养妇科癌症治疗与研究的人力。
Int J Gynecol Cancer. 2021 Oct;31(10):1380-1381. doi: 10.1136/ijgc-2021-002480. Epub 2021 Mar 16.
5
The Asia and Oceania Federation of Obstetrics and Gynecology, Women's Health, and Shan Ratnam.
J Obstet Gynaecol Res. 2003 Aug;29(4):268-75. doi: 10.1046/j.1341-8076.2003.00111.x.
6
COVID-19 and gynecological cancers: Asia and Oceania Federation of Obstetrics and Gynecology oncology committee opinion.COVID-19 与妇科癌症：亚洲大洋洲妇产科肿瘤学会意见。
J Obstet Gynaecol Res. 2021 May;47(5):1643-1650. doi: 10.1111/jog.14579. Epub 2021 Mar 1.
7
Impact on Women's Health: Gene Therapy in Gynecologic Oncology.对女性健康的影响：妇科肿瘤学中的基因治疗。
Hum Gene Ther. 2020 Mar;31(5-6):271-272. doi: 10.1089/hum.2020.29113.trf.
8
Gynecologic oncology on the global health agenda: A wake-up call.全球卫生议程中的妇科肿瘤学：一记警钟。
Gynecol Oncol. 2021 May;161(2):336-338. doi: 10.1016/j.ygyno.2021.02.033. Epub 2021 Mar 6.
9
Strategies and goals: the future of the International Gynecologic Cancer Society: IGCS Presidential Address.策略与目标：国际妇科癌症协会的未来：国际妇科癌症协会主席致辞
Int J Gynecol Cancer. 2010 Dec;20(9):1434-9. doi: 10.1097/IGC.0b013e318202df07.
10
SGO future forward: Our greatest challenges are our greatest opportunities.
Gynecol Oncol. 2010 Sep;118(3):212-5. doi: 10.1016/j.ygyno.2010.06.001. Epub 2010 Jun 23.

本文引用的文献

1
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).奥拉帕利维持治疗联合帕博利珠单抗和贝伐珠单抗治疗非突变型铂敏感复发性卵巢癌患者的单臂 II 期研究（OPEB-01）。
J Gynecol Oncol. 2021 Mar;32(2):e31. doi: 10.3802/jgo.2021.32.e31. Epub 2021 Jan 27.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
ENGOT与妇科肿瘤学组基金会（GOG Foundation）对与行业合作伙伴开展试验的联合要求。
Int J Gynecol Cancer. 2019 Sep;29(7):1094-1097. doi: 10.1136/ijgc-2019-000441. Epub 2019 Jul 18.
4
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.欧洲妇科肿瘤试验组织网络对学术团体与行业合作伙伴间试验的要求——2015年首次更新
Int J Gynecol Cancer. 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.0000000000000478.
5
Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.欧洲妇科临床试验网络（ENGOT）试验路线图。
Int J Gynecol Cancer. 2013 Sep;23(7):1339-43. doi: 10.1097/IGC.0b013e31829b87da.